Akums Drugs and Pharmaceuticals Limited — Investor Meet, 08-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Akums delivered a robust Q1 FY27. Revenue rose 13.9% YoY to 1,167 Cr, with EBITDA surging 35.4% to 175 Cr (15.0% margin). PAT climbed 56.1% to 101 Cr (8.4% margin).

Growth was primarily driven by the CDMO segment, showing double-digit volume gains. The API segment is nearing EBITDA positive, and trade generics broke even. A strategic highlight was the 56 Cr acquisition of Oriflame's manufacturing business, expanding Akums into skincare, cosmetics, and wellness, enhancing niche capabilities, and opening export potential. Management expresses confidence in continued growth.